NEWS

    2022
    01-21
    Credo Diagnostics will be present at Medical Japan Osaka in February 2022

    Taiwan, January 21, 2022 –Credo Diagnostics will be present at Medical Japan Osaka in February 24-26, 2022. Please come and visit our booth!

     

    Medical Japan is Japan’s leading trade show consisting of specialized shows for the Medical, Elderly Care and Pharmacy industries. The show will exhibit Medical IT, IT systems for hospitals, medical/hospital supplies, disposables, medical equipment, rehabilitation equipment, diagnostic equipment, clinical testing, advanced medical technologies, regenerative medicine, medical equipment development and manufacturing, pharmaceutical manufacturing, etc.

     

    Credo Diagnostics will show a true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. Being conscious of the necessity to simplify processes and accelerate molecular testing at affordable costs, Credo Diagnostics has the leading position in providing effective rapid POC Molecular Diagnostics. At Medical Japan Osaka, a Japanese interpreter will also serve at our booth for further inquiries. We are pleased to invite you to visit our booth and get to know the most innovative POCT solution and rapid molecular diagnostic platform, VitaPCR™

     

    【Medical Japan 2022 Osaka】

    ◾ Date: February 24 (Thu) - 26 (Sat), 2022

    ◾ Venue: INTEX Osaka, Japan(Virtual and Online)

    ◾ Booth No.: 9-21

    ◾ Exhibition Website: https://www.medical-jpn.jp/osaka/ja-jp.html

    ◾ E-Invitation Ticket: E-Invitation Ticket

     

     

     


     

    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2022
    01-14
    VitaPCR™Sample Collection Buffer Shows the Capability of Inactivating the SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV)

    Taiwan, January 14, 2022--SARS-CoV-2, Influenza virus, and Respiratory syncytial virus (RSV) are the well-known pathogens responsible for several contagious respiratory diseases, which can cause mild to severe illness and even death. These pathogens can spread very quickly from person to person, simply by touching or breathing in virus-containing particles. A case in point is COVID-19, it has been the most prevailing contagion worldwide since late 2019. To identify the disease, billions of specimens have been collected by the frontline healthcare operators every day to perform the respective diagnostic tests. Therefore,  it is crucial to implement appropriate measures to reduce the risk of virus exposure and protect the healthcare operators carrying out the tests

     

    In a study published in Nature Scientific Reports1, our VitaPCR™ Sample Collection Buffer was shown to effectively inactivate SARS-CoV-2 virus. In another inactivation study done by an external laboratory, treatment with the VitaPCR™ Sample Collection Buffer for 1 minute is capable of reducing Influenza A Virus, Influenza B Virus, and RSV titer by ≥ 4 log10 PFU/mL. Therefore, as the first step in our tests2 procedures, by mixing the patients’ swabs into our VitaPCR™ Sample Collection Buffer, the risk of virus exposure on testing operators is greatly reduced and therefore their safety is not compromised.  

     

    As a leader in the development of advanced medtech diagnostics solutions, Credo Diagnostics is proud to announce that we have dedicated ourselves to not only providing excellent and accurate diagnostic solutions, what we have designed ensures that the operators in the front line are safe – truly in line with our mission of improving the lives of those we love. With the inactivation effectiveness on SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and RSV, there is no doubt our VitaPCR™ Sample Collection Buffer is one of the ideal tools in our VitaPCR™ solution.

     

    For more information, please contact us at service@credodxbiomed.com

     

    1.Davies, K., Arnold, U., Buczkowski, H. et al.Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Sci Rep11, 23379 (2021). https://doi.org/10.1038/s41598-021-02942-4

    2. The VitaPCR™ Sample Collection Buffer is provided in VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Flu A&B Assay, VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay, and VitaPCR™ Flu/RSV Assay


     

    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2022
    01-12
    Credo VitaPCR™ system is on board! To work with Explorer Dream to resume cruises in Taiwan.

    Taiwan, January 12, 2022 – Credo Diagnostics, a leader in the development of advanced MedTech diagnostics solutions, is proud to announce that we have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號). By providing a true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology, cruise tours were able to resume.

     

    In a close-contact environment like the cruise ship, the transmission risk of SARS-CoV-2 from person to a person significantly increases with the movement of large numbers of people in such a closed setting. Therefore, in addition to social distance and regular sanitization measures, testing for COVID-19 is also an important way to protect everyone regardless of vaccination status. The VitaPCR™ SARS-CoV-2 Assay, based on the proprietary RT-PCR technology, enables COVID-19 detection in 20 minutes to provide timely diagnosis, helping healthcare personnel make accurate and immediate healthcare management decisions on board.

     

    Our VitaPCR™ SARS-CoV-2 Gen 2 Assay is able to detect COVID19 in 20 minutes with the all-important Ct value. By providing quick and accurate testing, the safety of the staff and crew members and passengers was not compromised. Importantly, Credo Diagnostics solution helps open up the resumption of the luxury cruise industry.

     

       

    Credo Diagnostics have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號)

     

       

    Credo Diagnostics solution helps open up the resumption of the luxury cruise industry.

     

     



    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2022
    01-10
    Credo Diagnostics nabs CE mark for VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets

    Taiwan, January 10, 2022 –Credo Diagnostics Biomedical Pte. Ltd. is delighted to announce that both VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets have obtained the CE IVD mark. These control sets are intended to be used for quality control testing with a series of VitaPCR™ Assays (exclude VitaPCR™ SARS-CoV-2 Assay, Cat# PCRAE0114)

     

    VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets consist of droppers and disposable positive controls. The positive control is noninfectious in-vitro transcribed RNA in a lyophilized state, which can be conveniently stored at room temperature. With the control sets, the user is able to conduct quality testing to affirm the assay performance anywhere and anytime without the risk of control degradation and contamination.

     

    VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets are recommended to be used during each time a new shipment of kits is received or when training a new operator; or in accordance with local regulations, accrediting groups, or laboratory’s standard quality control procedures.

     

    For more information, please contact: service@credodxbiomed.com

     


     

    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2022
    01-07
    VitaPCR™ sample collection buffer can inactivate SARS-CoV-2 effectively

    Taiwan, January 7, 2022 –For all diagnostic procedures to test COVID-19, performing these tests at POC or near-POC requires a suitable and sufficient risk assessment and implementation of appropriate control measures. It is essential that the rapid testing procedure, which may involve swab stirring/mixing into an elution buffer with the potential for associated generation of aerosols, does not place individuals performing these tests at an increased risk of SARS-CoV-2 exposure. It is therefore highly desirable that rapid testing procedures include a step that reduces the titer of infectious virus presents, e.g., by eluting samples into an effective lysis buffer.

    In a study to assess the inactivation effectiveness of sampling buffers used, the UK National Infection Service (NIS) laboratories recently published in the Nature Scientific Reports to demonstrated the VitaPCR™ sample collection buffer is able to inactivate SARS-CoV-2 effectively, which provides clinicians in the front line with sufficient protection against SARS-CoV-2.

    According to the study results, a >5.0 log10 reduction in SARS-CoV-2 titer was confirmed after one-minute treatment with VitaPCR™ sample collection buffer, which went up to 6.2 log10 reduction after a five-minute mixing. Data presented in this study showed the capability of VitaPCR™ sample collection buffer to ensure the protection of test operators, which also meets the requirement of the British European standard BS EN 14476 for effectiveness against viruses.

    VitaPCR™ sample collection buffer, the next-generation (guanidine-free) nucleic acid extraction buffer, not only inactivates SARS-CoV-2 during contact but also eliminates the chemical hazards associated with conventional guanidine-based reagents in diagnostic procedures.

    For more information, please refer to https://rdcu.be/cEsqk or contact us at: service@credodxbiomed.com



    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

     

    view more
    2022
    01-01
    The establishment of Credo Diagnostics Biomedical Pte. Ltd. Taiwan Branch for delivering the highest quality medical solutions

    Taiwan, January 1, 2022 –It is with great pleasure that we announce the establishment of our Branch in the Republic of China, Taiwan. This important milestone comes as part of our continuous efforts to expand our reach and make our products and services as widely available as possible. Importantly, this initiative continues our focus, ADVANCED MEDTECH FOR ALL.

    The choice of Taiwan is very clear.

    “As a member of international organisations such as the World Trade Organisation (WTO) and the Asia Pacific Economic Cooperation (APEC), Taiwan is highly free in economic activities. Coupled with its economic stability and measures being taken to cut red tape and remove bureaucracy from business procedures, it was an easy decision”, said Dr. Winston Wong Jr., Chairman and CEO of Credo Diagnostics Biomedical.

    “Besides, Taiwan has demonstrated that their diversified pool of biotech talents has high-quality standards. In addition to their outstanding medical system, Taiwan offers a comprehensive supply chain for the biomedical industry. Taking advantages of the many business friendly offerings in Taiwan, Credo Diagnostics aims to provide excellent and accurate medical solutions to improve the lives of people around the world.”

     


    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


    Media Contact:
    Cheryl Yang
    Tel: +886 2-2697-3998 Ext.1116
    Email: cheryl.yang@credodxbiomed.com

     

    view more